Time interval and imaging examinations
| Included trials | Exam | Time interval | Response considered |
| Spira et al20 | MRI | At baseline and follow-up every 8 weeks (range, 2–19 weeks; mean, 7.6 weeks). | Target response |
| Edeline et al16 | CT | 1 CT scan in the first and second months and every 2 months thereafter. | Target response |
| Moschouris et al22 | CT/MRI | 1–5 days prior to the initiation of antiangiogenetic treatment; follow-up studies were performed approximately every 2 months (range: 7–10 weeks) after the first dose of the drug. | Target response |
| Kawaoka et al21 | CT/MRI | At 8 weeks from the date of administration of sorafenib. | Overall response |
| Arizumi et al23 | CT/MRI | Every 4–6 weeks during and after treatment. | Overall response |
| Bargellini et al24 | CT | 4±2 weeks before and 8±2 weeks after initiation of sorafenib treatment. | Overall response |
| Ronot et al14 | CT | 6 weeks before sorafenib and had the first tumour evaluation with a second CT scan within 1–3 months after sorafenib initiation. | Overall response |
| Salvaggio et al25 | CT/MRI | Baseline examinations were performed at a median of 30 days (range 28–36 days) before the start of treatment. Follow-up imaging study available was performed after a median of 103 days (range 55–617 days). | Target response |
| McNamara et al26 | CT | Tumour response was assessed every 8 weeks via CT. | Overall response |
| Takada et al15 | CT | Within 1 month of commencing treatment and every 1–2 months during treatment. | Overall response |
| Gavanier et al27 | CT | Within 6 weeks before sorafenib administration; and Imaging available during sorafenib therapy (>4 weeks after initiation). | Overall response |
| Ikeda et al28 | CT/MRI | Tumour response was evaluated every 8 weeks. | Overall response |
| Pelosof et al29 | CT/MRI | Tumour assessments were performed every 6 weeks for the first eight cycles, then every 12 weeks thereafter. | Overall response |
| Kaneko et al30 | CT | CT was performed at baseline and every 4–8 weeks after LEN administration. | Overall response |
| Kawamura et al31 | CT | We assessed the best tumour response during 2–12 weeks. | Overall response |
| Kuzuya et al32 | CT | CT examination was performed with a predetermined schedule at baseline and at 6 weeks after ramucirumab initiation. | Overall response |
| Maruta et al33 | CT/MRI | Every 1–2 months after starting treatment for the evaluation of tumour response. | Overall response |
| Yamamichi et al34 | CT | CT was performed at baseline (before initiation of treatment) and at every 2–3 months afterward. | Overall response |
| Murakami et al19 | CT | CT was performed at baseline (before initiation of treatment) and at every 2–3 months afterward. | Overall response |
| He et al35 | CT/MRI | Upper abdomen-enhanced CT (or MRI) was performed at baseline and every 6 weeks (±1 week). | Overall response |
| Nair et al36 | CT/MRI | Enhanced CT or MRI was performed at baseline and every 8 weeks. | Overall response |
| Salem et al37 | CT/MRI | Enhanced CT or MRI was performe at baseline and every 6 weeks. | Target response |
| Yamashige et al38 | CT | Enhanced CT was performed at baseline and every 2–12 weeks. | Target response |
LEN, Lenvatinib.